FOXO4-DRI
A designer peptide that selectively triggers apoptosis in senescent cells, an emerging anti-aging strategy.
Overview
FOXO4-DRI is a designed peptide that disrupts the interaction between FOXO4 and p53 in senescent cells, releasing apoptotic signaling that selectively eliminates these 'zombie cells.' It's one of the most discussed senolytic peptides in longevity research.
Benefits
- Selectively clears senescent cells
- Healthy cells remain unaffected
- May reverse aspects of aging in animal models
- Improves tissue function in preclinical work
Mechanism of Action
Disrupts FOXO4-p53 binding specifically in senescent cells, freeing p53 to trigger apoptosis only in cells that depend on this interaction for survival.
Dosage (informational only)
- Typical range
- 5 mg/kg in animal models — human dosing not established
- Frequency
- Cycle protocols vary in research
Human safety data is extremely limited. Use is investigational.
Side Effects
- Limited human data
- Possible immune flares from cell clearance
- Theoretical off-target apoptosis risk
Related peptides
A mitochondrial-derived peptide studied for metabolic regulation, insulin sensitivity, and exercise capacity.
A synthetic tetrapeptide developed in Russia, studied extensively for telomerase activation and aging biomarkers.
A nine-amino-acid neuropeptide first identified for its sleep-promoting effects, now studied for stress and circadian regulation.